Australian clinical-stage immuno-oncology company Imugene (ASX: IMU) today announced that it would acquire Vaxinia Pty Ltd via a cash and share deal valued at A$1.619 million ($1.13 million).
Also, Imugene has acquired a worldwide exclusive license to a promising oncolytic virus technology, known as CF33, developed at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases based in Los Angeles, California, USA.
News of the deals saw Imugene’s shares close down 6.25% at A$0.015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze